您的位置： &
ADI公司将高保真音质技术引入D类放大器——ADI公司的新型D类音频放大器瞄准高级电视和汽车应用，以高达2X40W功率提供顶级性能并且减小EMI
优质期刊推荐网站综合评估
请输入您要评估的网址：
AG官网-ag亚游集团官网-让客户得到最好的体验
网站域名：
网站标题：AG官网-ag亚游集团官网-让客户得到最好的体验
网站简介：
AG官网从中国民用航空局新闻发布会获悉 为了加强民航行业信用文化建设，维护民用航空活动秩序，民航行业{关键词}管理办法（试行）》（以下简称《{关键词}》）已于日前正式签发，明确界定一般{关键词}行为和15种{关键词}行为，将从明年1月1日起试行，关于ag亚游集
网站关键字：
网站价值：
-元(不含域名价值,品牌价值及其附加值)
网站可信度：
1分(网站可信度评估分值仅供参考，评分结果从1-10分不等)
日广告收入：
网站影响力：
在业界影响力较小！
备案情况：
复制本页地址：
http://www.iapolo.com/k_www.happytwofilm.com.html
评估时间： 21:55:05&&&&
www.happytwofilm.com网站综合价值评估简报
www.happytwofilm.com网站评估价值为-元，预测该网站每天约有0个访客，其中电脑端0IP，移动端0IP，网站日广告收入约0元。谷歌对该网站评分为0，搜狗对该网站评分为0，百度为该网站评分为0，360为该网站评分为
，该网站在世界排名第0位。该网站有的历史，创建于，该网站ip：121.42.80.51，网站服务器位于China Beijing，
在业界影响力较小！
www.happytwofilm.com网站评论信息
佚名：AG官网-ag亚游集团官网-让客户得到最好的体验很强大，这个阿波罗评估平台必须收藏，评估的很准！
匿名：你的www.happytwofilm.com是很有发展潜力的站，加油！
匿名：这个网站价值评估工具不错，查询各项数据挺全面实用的，以后查询自己的网站价值就用这个了，收藏了！
点评：网站很不错，服务很到位，技术团队实力雄厚，对客户的要求能尽量满足，不错！！超赞！！！
您的帐号尚未登录，请
Alexa排名：
日IP估值：
PC流量估值：
移动流量估值：
日PV估值：
百度权重：
搜狗评级：
免费SEO优化报告
阿波罗评估免费SEO优化报告采用百度、Google等搜索引擎算法作为标准。
[正确]---title标签设置合理。
keywords：
[正确]---keywords标签设置合理。
description：
[警示]---description设置长度过长。建议长度220字符以内。
javascript：
[建议]---Javascript脚本建议写到.js文件中，有利于搜索引擎抓取
style样式：
[建议]---CSS样式建议写到.css文件中以缩减代码的繁琐度有利于搜索引擎抓取
flash/object：
[建议]---flash/object加上相关说明文字，有利于搜索引擎识别内容
图片Alt信息：
[警示]---存在没有alt信息的img标签,加入这项信息可使您网页上的图片更容易被用户检索到
frame信息：
[建议]---frame/frameset/iframe标签会导致spider的抓取困难，建议您尽量不要使用
[建议]---百度建议url的最长长度不超过255byte
html标签：
[正确]---html标签设置合理。
百度快照：
[提示]---百度官方已取消百度快照。
百度当日收录：
[警告]---百度当日没有新收录，请注意加强SEO优化。
百度当日收录
百度本周收录
百度本月收录
已取消快照
121.42.80.51
托管地址：
China Beijing
所在地址：
Whois服务：
域名状态：
注册时间：
到期时间：
域名年龄：
域名 happytwofilm 其他后缀评估信息
网站缩略图[首次生成需要1-10分钟]
&div style=&border: 1px solid # background-color: width:150 height:60 text-align: &&&p style=&margin:5&&&a href=&http://www.iapolo.com/k_www.happytwofilm.com.html&&&span style=&font-size:12&&我的网站价值:&br /& &font color=&green&&&b&￥-&/b&&/font&.&/span&&/a&&br /&&span style=&font-size: 12&&&a href=&http://www.iapolo.com/&&你的网站价值多少?&/a&&/span&&/p&&/div&
相关评估记录
,,,,,,,,,,,,。
快来评估一下您的网站、博客值多少钱。免费提供网站SEO检测报告，为您网站的优化提供有价值的参考。注：Google有时不稳定，如果其收录与PR值显示为0，请稍后再试。
, WWW.Iapolo.COM. All rights reserved.您的位置： &
恰好时闪耀亮相体博会
优质期刊推荐Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
United States Patent 6080751
A method of treating human pancreatic cancer with water-insoluble 20(S)-camptothecin compounds with the closed-lactone ring intact and/or derivatives thereof is disclosed. The method includes preferably administering the compounds intramuscularly, orally, and transdermally.
Inventors:
Stehlin, John S. (Houston, TX)
Natelson, Ethan A. (Houston, TX)
Giovanella, Beppino C. (Houston, TX)
Kozielski, Anthony J. (Houston, TX)
Application Number:
Publication Date:
06/27/2000
Filing Date:
09/13/1996
Export Citation:
The Stehlin Foundation for Cancer Research (Houston, TX)
Primary Class:
International Classes:
A61K31/44; (IPC1-7): A61K31/44
Field of Search:
View Patent Images:
&&&&&&PDF help
US Patent References:
5225404Giovanella et al.514/2835180722Wall et al.514/2195162532Comins et al.546/485155225Fortunak et al.546/485145684Liversidge et al.424/4895126351Luzzio et al.514/2915122606Wani et al.546/485122526Wall et al.546/485106742Wall et al.514/2835064823Lee et al.514/985061800Yaegashi et al.546/485061795Tagawa et al.546/485053512Wani et al.546/485049668Wall et al.546/485041424Saulnier et al.514/275004758Boehm et al.514/2834981968Wall et al.546/484943579Vishnuvajjala et al.514/2834939255Tagawa et al.546/484914205Sawada et al.546/484904768Saulnier et al.536/17.14894456Wall et al.546/484874779Senter514/4104867978Gold424/1664774236Cook et al.546/48RE32518October, 1987Miyasaka et al.546/484604463Miyasaka et al.546/484545880Miyasaka et al.204/1584513138Miyasaka et al.546/484473692Miyasaka et al.546/484399282Miyasaka et al.546/484399276Miyasaka et al.546/484357422Giard et al.435/684031098Sugasawa424/2583894029Winterfeldt et al.424/2580032518N/A
Foreign References:
EP0074256Camptothecin derivatives, processes for preparing same, formulations containing such derivatives and their use.EP0220601Pyranoindolizine derivatives and preparation process thereof.EP041809910, 11-Methylenedioxy-20 (RS) camptothecin and 10, 11-methylenedioxy-20 (S) - camptothecin analog.EP0540099Water soluble camptothecin derivatives.JP6150985March, 1983JP0595188January, 1984JPMarch, 1984JP5951289March, 1984JP6185319April, 1986JP6185389April, 1986WOA1CAMPTOTHECIN ANALOGS AS POTENT INHIBITORS OF HUMAN COLORECTAL CANCERWOA1METHOD FOR TREATING RETROVIRAL INFECTIONS IN MAMMALSJPS6185319AJPS5951289AJPHAJPSAJPS595188AJPS6185389A
Other References:
1992 AACR Abstract Form, "Pharmacokinetics of Tritum Labeled Camptothecin in Nude Mice," Smith, P.L. et al.
1992 AACR Abstract Form, "Growth Inhibition of Human cancer Metasteses in the Xenograft Model by Camptothecin [NSC 94600], 9-amino (NSC 60371] and 9-nitrocamptothecin," Potmesil, M.
Giovanella et al., Cancer Research, vol. 51, pp. , Jun. 1, 1991.
Kharbanda et al., Cancer Research, vol. 51, pp. , Dec. 15, 1991.
The Alkaloids, vol. XXV, Chapter 1, "Antitumor Alklaoids," Suffness et al., pp. 73-89, copyright 1985, Academic Press, Inc.
Wall et al., "New Type of 9-Nitrocamptothecin and a Method of its Production," J. Am. Chem. Soc., vol. 88, No. 16, pp. , Aug. 20, 1966.
Hsiang, Y.-H. et al., Cancer Res. 48: , 1988.
Wani, M.C. et al., J. Med. Chem. 30: , 1987.
Wani, M.C. et al., J. Med. Chem 29: , 1986.
Hsiang, Y.-H. et al., J. Biol. Chem 97: , 1985.
Hsiang, Y.-H. et al., Abstract 683 from The American Association for Cancer Research, vol. 29, Mar. 1988.
Wall, M.E. et al., J. Med. Chem. 29: , 1986.
Nelson, W.G. et al., Cancer Res. 47: , 1987.
Hsiang, Y.-H. et al., Cancer Res. 49: , 1989.
Wani, M.C. et al., J. Med. Chem. 30: , 1987.
Giovanella, B.C. et al., Cancer 52: , 1983.
Wani, M.C. et al., J. Med. Chem. 23: 554-560, 1980.
Leibovitz, A. et al., Cancer Res. 36: , 1976.
Fogh, J. et al., in "Human Tumor Cells In Vitro," Fogh, Jr. et., Plenum Press, New York, 1976, pp. 115-141.
Liu, L.F. et al., Proc. Nat'l. Acad. Sci. USA, 78: , 1981.
Muggla, F.M. et al., Cancer Chemo. Rep. 56: 515-521, 1972.
Gottlieb, J.A. et al., Cancer Chemo. Rep. 54: 461-470, 1970.
Jaxel,C. et al., Cancer Res. 49: , 1989.
Potmesil, M. et al., Cancer Res. 48: , 1988.
Chemical Abstracts, vol. 106(25), Abstract No. 207285z (1987).
Chemical Abstracts, vol. 106(15), Abstract No. 120133z (1987).
Chemical Abstracts,vol. 106(15), Abstract No. 11479a (1987).
Chemical Abstracts,vol. 106(13), Abstract No. 95753s (1987).
Chemical Abstracts, vol. 103(9), Abstract No. 64374c (1985).
Chemical Abstracts, vol. 101, Abstract No. 130677r (1984).
Chemical Abstracts, vol. 101(11), Abstract No. 91322z (1982).
Chemical Abstracts, vol. 101(10), Abstract No. 78770z (1984).
Chemical Abstracts, vol. 100(21), Abstract No. 167724j (1983).
Chemical Abstracts, vol. 100, Abstract No. 139434w (1984).
Chemical Abstracts, vol. 97, Abstract No. 188278b (1982).
Chemical Abstracts, vol. 96(9), Abstract No. 69271p (1981).
Chemical Abstracts, vol. 95(15), Abstract No. 133209h (1981).
Chemical Abstracts, vol. 94(1), Abstract No. 4143n (1980).
Chemical Abstracts, vol. 92(5), Abstract No. 37766e (1980).
Chemical Abstracts, vol. 92(3), Abtract No. 18799b (1980).
Chemical Abstracts, vol. 90(4), Abstract No. 28930k (1979).
Chemical Abstracts, vol. 90(3), Abstract No. 22857v (1979).
Chemical Abstracts, vol. 84, Abstract No. 115629p (1976).
Chemical Abstracts, vol. 94(12), Abstract No. 90169e (1980).
Derwent 89-.
Nicholas et al., J. Med. Chem., vol. 33, No. 3, pp. 972-978, 1990.
Ohro et al., Proc. Ann. Meet Am. Soc. Clin. Oncol., 8: A.
Hertzberg et al., J. Med. Chem., vol. 32(3), pp. 715-720, 1989.
Hsiang et al., Proc. Ann. Meet. Am. Assoc. Cancer Res., 30: A.
Hertzberg et al., Proc. Ann. Meet. Am. Assoc. Cancer Res., 30: A.
Pommier et al., Proc. Ann. Meet. Am. Assoc. Cancer Res., 29: A.
Lin et al., Yao Hsueh Hsueh Pao, vol. 23(3), pp. 186-188 (1988).
Ronman et al., Journal of Labelled Compounds and Radiopharmaceuticals, vol. 18(3), pp. 319-329, 1981.
Danishefky et al., J. Org. Chem., vol. 39(28), pp. , 1974.
Plattner et al., J. Org. Chem., vol. 39(3), pp. 303-311, 1974.
Plattner et al., J. Amer. Chem. Soc., vol. 94(24), pp. , 1972.
Govindachari et al., "9-Methoxycamptothecin: a New Alkaloid from Mappie voetida Miers,"pp. 453-454.
Giovanella et al., Science, vol. 246, pp. , 1989.
Xi-Ran et al., "Topical Camptothecine in Treatment of Psoriasis," Int'l Journal of Dermatology, vol. 27, No. 7, pp. 475-476, Sep. 1988.
Ching-jung et al., "Effect of Topical Use of Camptothecine-Dimethyl Sulfoxide Solution in Psoriasis," Chinese Medical Journal, vol. 1, No. 5, pp. 355-360, Sep. 1975.
Tung et al., "Camptothecin Instillation and Local Injection for Prevention and Treatment of Urinary Bladder Tumors," Chinese Medical Journal, vol. 92, No. 1, pp. 57-60, 1979.
Pantazis et al., "Complete Inhibition of Growth Followed by Death of Human Malignant Melanoma Cells in Vitro and Regression of Human Melanoma Xenografts in Immunodeficient Mice Induced by Camptothecin," Cancer Research, vol. 52, No. 14, pp. , Jul. 15, 1992.
Cancer Research 5. , Jul. 15, 1992; "Complete Inhibition of Growth followed by Death of Human Malignant Melanoma Cells in Vitro and Regression of Human Melanoma Xenografts in Immunodeficient Mice Induced by Camptothecins.sup.1."
Primary Examiner:
Goldberg, Jerome D.
Attorney, Agent or Firm:
Armstrong, Westerman, Hattori, McLeland & Naughton
Parent Case Data:
This application is a continuation-in-part of
U.S. Ser. No. 08/474,761, filed Jun. 7, 1995, now U.S. Pat.
No. 5,652,244 which is a continuation of U.S. Ser. No.
08/002,844, filed Jan. 15, 1993, abandoned which is a
continuation-in-part of U.S. Ser. No. 07/820,334, filed Jan.
14, 1992, abandoned, and also a continuation-in-part of U.S.
Ser. No. 07/432,066, filed Nov. 6, 1989, now U.S. Pat. No.
5,225,404.
What is claimed is:
1. A method of treating pancreatic cancer in a human comprising administering to said human an effective amount of a water-insoluble 20(S)-camptothecin compound with a closed-lactone ring, a derivative thereof or mixture thereof, wherein said 20(S)-camptothecin compound is 20(S)-camptothecin, 9-Nitro-20(S)-camptothecin, 9-Amino-20(S)-camptothecin, or a mixture thereof, and wherein said effective amount is at least about 1 mg/day.
2. The method of claim 1, wherein said 20(S)-camptothecin compound is 9-Nitro-20(S)-camptothecin.
3. The method of claim 1, wherein said 20(S)-camptothecin compound is administered orally.
4. The method of claim 1, wherein said 20(S)-camptothecin compound is administered or intramuscularly.
5. The method of claim 1, wherein said 20(S)-camptothecin compound is administered transdermally.
6. The method of claim 1, wherein said 20(S)-camptothecin compound is 9-amino-20(S)-camptothecin.
7. The method of claim 1, wherein said 20(S)-camnptothecin compound is 20(S)-camptothecin.
8. The method of claim 1, wherein said effective amount is from about 1 mg/day to about 4 mg/day.
9. The method of claim 1, wherein said effective amount is from 1 mg/day to 4 mg/day.
Description:
FIELD OF THE INVENTIONThe present invention relates to a method for treating pancreatic cancer in humans. BACKGROUND OF THE INVENTION 20(S)-camptothecin (CPT), a plant alkaloid, was found to have anticancer activity in 1966 (Wall, M., Wani, M. C., Cooke, C. E., Palmer, K. H., McPhail, A. T. and Slim, G. A. "Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata", J. Am. Chem. Soc. 88: , 1966). During the sixties and seventies the sodium salt of CPT was derived from CPT, and clinical trials of this chemically altered CPT were carried out and then abandoned because of the high toxicity and low potency of this compound (Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T. and Block, J. B. "Preliminary pharmacological and clinical evaluation of camptothecin sodium salt (NSC 100880)", Cancer Chemother. Rep. 54: 461-470; 1979; Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. N. and Selawry, D. S. "Phase I clinical trials of weekly and daily treatment with camptothecin (NSC 100880). Correlation with clinical studies." Cancer Chemother. Rep. 56: 515-521; 1972; Gottlieb, J. A. and Luce, J. K. "Treatment of malignant melanoma with camptothecin (NSC 100880)." Cancer Chemother. Rep. 56: 103-105; 1972; and Moertel, C. G., Schutt, A. J., Reitemeier, R. J. and Hahn, R. G. "Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer." Cancer Chemother. Rep. 56: 95-101; 1972. All these trials were conducted using the hydrosoluble, sodium salt derivative of CPT (CPT Na+), which was administered via i.v. The research of the present inventors has fully confirmed the ineffectiveness and the toxicity of CPT Na+. Experiments have demonstrated that the non-water soluble CPT is nontoxic and highly effective as an anticancer agent. Furthermore, the present inventors have demonstrated that the intramuscular and oral administration provide unexpectedly better results than the intravenous administration. Drug therapies have been evaluated with respect to treating human cancer, e.g., human cancer xenograft lines. Human tumors are serially heterotransplanted into immunodeficient, so-called "nude" mice, and the mice then tested for their responsiveness to a specific drug. (Giovanella, B. C., et al., Cancer 52(7):)). The data obtained in these studies strongly support the validity of heterotransplanted human tumors into immunodeficient mammals, such as nude mice, as a predictive model for testing the effectiveness of anticancer agents. It was determined that 9-Amino-20(S)-Camptothecin (9AC) and 10,11-Methylendioxy-20(S)-Camptothecin (10,11MD) are capable of having high anticancer activity against human colon cancer xenografts (Giovanella, B. C., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R. and Potmesil, M. "Highly effective topoisomerase-I targeted chemotherapy of human colon cancer in xenografts." Science 246: ; 1989). After this finding, the present inventors extended these studies to other human cancers growing as xenografts in nude mice as well as conducted studies on the administration of CPT and its derivatives. It is important to note that the fundamental difference between the chemical used by the present invention (CPT) and the one used ineffectively and with high attendant toxicity in the past (CPT Na+) is that CPT is water-insoluble and CPT Na+ is water-soluble. SUMMARY OF THE INVENTION An object of the present invention is to provide a novel method for treating pancreatic cancer in humans. Additional objects and advantages of the present invention will be set forth in part in the description which follows, and in part will be apparent from the description, or may be learned by practice of the present invention. The objects and advantages of the present invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. To achieve the objects and in accordance with the purpose of the present invention, as embodied and broadly described herein, the present invention relates to a method for treating pancreatic cancer in a human which comprises administering an effective amount of a water-insoluble 20(S)-Camptothecin (CPT) with the closed-lactone ring intact or a derivative thereof or a mixture thereof, preferably 9-nitro-20(S)-camptothecin. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the present invention, as claimed.
BRIEF DESCRIPTION OF THE DRAWING The Figure is a graph showing the results obtained by administering 9-Nitro-20(S)-camptothecin to a human having pancreatic cancer.
DESCRIPTION OF THE PREFERRED EMBODIMENT(S) While treatment of mammals with 20(S)-camptothecin compounds showed promise for treating various forms of cancer, upon using camptothecin compounds with humans, it was found that the success rate was less than expected in view of the results achieved with mice. Thus far, a success rate of partial and/or complete remissions of various cancer tumors in humans was achieved with various 20(S)-camptothecin compounds. It was quite unexpected that by treating pancreatic cancer in humans with 20(S)-camptothecin compounds and preferably 9-Nitro-20(S)-camptothecin or 9-Amino-20(S)-camptothecin, that a partial and/or complete remission occurred in at least about 35% of the human patients treated. CPT is a plant alkaloid isolated from Camptotheca acuminata. Chemical derivatives of CPT can be prepared either in a semisynthetic or totally synthetic way. (See, e.g., Wani, M. C. et al., J. Med. Chem. 23:544, 1980; Wani, M. C. et al., J. Med. Chem. 30: ); and Wani, M. C. et al., J. Med. Chem. 30: )). In the example discussed below, the CPT was obtained from the Institute of Materia Medica, Academia Sinica, Shanghai, China, and further purified using standard chromatographic techniques. Camptothecin Sodium Salt (CPT Na+), 9-Nitro-20(S)-Camptothecin (9NO2) and 9-Amino-20(S)-Camptothecin (9AC) were also synthesized from CPT. CPT and derivatives thereof have to be extensively purified prior to administering for use in the present invention because: (1) the natural product contains several other components which have a large degree of toxicity for example, in mice, and (2) FDA regulations require such purifying for any drug or compound to be used as a medicine. Methods of purification known by those skilled in the art can be used, e.g.--dissolving the CPT in a suitable solvent such as chloroform or methylene chloride and then adsorbing onto a column containing silica gel and then carrying out elution of the adsorbed materials by increasing the polarity of the eluant by adding, e.g., methanol. The purity of the compound can be tested by high performance liquid chromatography (HPLC) and thin layer chromatography (TLC) and other appropriate methods known in the art. The compound can also be completely characterized using infrared (IR), ultraviolet (UV) and nuclear magnetic resonance (NMR) spectroscopy and elemental analysis. Furthermore, the CPT and derivatives thereof used in the present invention are water-insoluble and not administered in the chemically and physically different sodium salt form. This difference can easily be observed by looking at their elemental analysis, NMR, UV and IR spectra and also by their different physical behavior in HPLC and TLC experiments. CPT and derivatives thereof of the closed lactone ring form are used and are administered in any form, preferably intramuscularly, orally, or transdermally and in some cases it was possible to obtain total remission of human pancreatic cancer. The derivatives of CPT for use in the present invention include, for example, 9NO2, and 9AC. A mixture of CPT and derivatives thereof can also be used in the present invention. Other related derivatives can also be used in conjunction with the method of the present invention. Examples include dimethylaminomethyl-10-hydroxy-20(S)-CPT (topotecan), 7-ethyl-10-[4-(1-piperdino)-1-piperdino]carbonyloxy-CPT (CPT-11), 7-ethyl-10-hydroxy-20(S)-CPT, 9-amino-20(S)-CPT, 9-nitro-20(S)-CPT, 10,11-methylenedioxy-20(S)-CPT, 9-chloro-20(S)-CPT, 9-bromo-20(S)-CPT, 9-hydroxy-20(S)-CPT, 11-hydroxy-20(S)-CPT, and 10-hydroxy-20(S)-CPT. Another method of administering the compounds of the present invention is by a transdermal or transcutaneous route. One example of such an embodiment is the use of a patch. In particular, a patch can be prepared with a fine suspension of a compound disclosed in the present application in, for example, dimethylsulfoxide (DMSO), or a mixture of DMSO with cottonseed oil and brought into contact with the skin of the tumor carrying mammals away from the tumor location site inside a skin pouch. Other mediums or mixtures thereof with other solvents and solid supports would work equally as well. The patch can contain the CPT compound in the form of a solution or a suspension. The patch can then be applied to the skin of the patient, for example, by means of inserting it into a skin pouch of the patient formed by folding and holding the skin together by means of stitches, clips or other holding devices. This pouch should be employed in such a manner so that continuous contact with the skin is assured without the interference of the mammal. Besides using a skin pouch, any device can be used which ensures the firm placement of the patch in contact with the skin. For instance, an adhesive bandage could be used to hold the patch in place on the skin. In the studies, the water-soluble derivatives of these compounds proved to be ineffective as anticancer agents and very toxic to mammals. Even the closed lactone ring forms of CPT and derivatives thereof showed a great difference in activity, depending on their route of administration. As used herein, the term "pancreatic cancer" is intended to encompass all forms of human pancreatic carcinomas, sarcomas, and melanomas which occur in the poorly differentiated, moderately differentiated, and well differentiated forms. In treating or retarding malignant tumors in mammals in accordance with the present invention, the aforedescribed camptothecin compounds are administered in any form, preferably intramuscularly, transdermally, or orally, using commonly known methods, for example, gelatin capsules for oral administration, as well as novel, superior formulations, such as microsuspensions in lipid and in lipid-like emulsions (e.g.--Intralipid 20, cottonseed oil and peanut oil) for intramuscular administration and inclusion in cholesterol pellets for subcutaneous long-term administration. As used herein, an "effective amount" of CPT and derivatives thereof described above is intended to mean that amount of the compound which will inhibit the growth of, or retard pancreatic cancer, or kill malignant pancreatic cells, and cause the regression and palliation of malignant pancreatic tumors, i.e., reduce the volume or size of such tumors or eliminate the tumor entirely. With humans, the effective amounts can be administered on the basis of body surface area. The interrelationship of dosages for animals of various sizes, species and humans (based on mg/M2 of body surface) is described by E. J. Freireich et al., Cancer Chemother. Rep., 50(4):219 (1966). Body surface area may be approximately determined from the height and weight of an individual (see, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, N.Y. pp. 537-538 (1970). An effective amount of the camptothecin compounds in the present invention can range from about 0.5 mg/m2 of body surface per day to about 2.0 mg/m2 of body surface per day, preferably about 1.0 mg/m2 of body surface per day to about 1.5 mg/m2 of body surface per day. Preferably, this dosage is administered each day for five days and then two days with no dosage, and so on. The exact timing of administration of the dosages can be varied to achieve optimal results. Another important feature of the method provided by the present invention relates to the relatively low or no apparent overall toxicity of the camptothecin compounds administered in accordance herein. Overall toxicity can be judged using various criteria. For example, loss of body weight in a subject over 10% of the initially recorded body weight (i.e., before treatment) can be considered as one sign of toxicity. In addition, loss of overall mobility and activity and signs of diarrhea or cystitis in a subject can also be interpreted as evidence of toxicity. The compounds of the present invention may be administered in combination with pharmaceutically acceptable carriers or diluents, such as Intralipid 10 or 20 or natural oils, or other suitable emulsifiers for lipophilic compounds. The present invention will be further clarified by the following example, which is intended to be purely exemplary of the present invention. EXAMPLE 1 Ten human patients diagnosed with pancreatic cancer were administered 9-nitro-20(S)-camptothecin. 9NO2 (also referred to as 9NC) was synthesized (Wani, M. C., Nicholas, A. W., Wall, M. E., Plant Tumor Agents. 23. Synthesis and antileukemic Activity of Camptothecin analogues, J. Med. Chem., , 1986) from CPT obtained from the Institute of Materia Medica, Academia Sinica, Shanghai, China. The derivatives were purified by chromatography and analyzed. A typical sample preparation for oral administration includes the dispersion of the test compound by sonication (3 pulses for 30 seconds each), using an Ultrasonic Processor, Model GE600 by Sonics and Materials, Inc., CT. The dosage of the 9-nitro-20(S)-camptothecin is set forth in Table 1, as well as the sex, age, and starting date of the treatment. To date, there have been two cases of complete remission, and other patients show signs of at least partial remissions. One patient has died, but it is noted that this patient did survive over a year and treatment with the 9-nitro-20(S)-camptothecin at least contributed to that survival of over a year. This is important because, without treatment, a patient has a life expectancy of about 4.6 months upon detection of the pancreatic tumor and with other known treatments has a life expectancy of about 5.5 to about 6.5 months. Thus, even though one patient has died, the patient's survival for over one year was still unexpected and superior to other forms of treatment. The patients set forth in Table 1 were administered the various dosages orally wherein crystalline 9-nitro-20(S)-camptothecin powder was administered in the form of gelatin capsules as described earlier.
______________________________________
Pancreatic Patients on 9NC
Total Dose
______________________________________
2.5 mg/daySubjective improve- has liver large centralmass--has goneback to work.Male
3/16/95 4.96
3.0 mg/dayComplete remission,(decreasedtumor-free overto 2.0 mg/one year.day 8/95)Male
6/23/95 2/20/964 mg/dayD Progression onCAT scan eventually,but did surviveover a year.Male
11/3/95 Present2.25 mg/dayComplete remission,tumor-freeover six months.Male
5/22/96 Present3.0 mg/day,Liver and peritonealincreased to3.25 mg/dayCEA antigen7/96
dropped from100 to 19;ascites gone.Male
2.25 mg/dayFemale56
3.00 mg/dayDeveloped low WBC;interrupted andrestarted.Male
2.00 mg/dayMale
3.5 mg/dayHas gained fivepounds and feelswell.Female52
______________________________________
As also described earlier, it is unexpected and superior to have out of ten patients, two complete remissions, overall favorable initial results regarding the other patients, and one patient who survived over a year before dying. With human patients having other forms of cancer being treated with 20(S)-camptothecin compounds, there has been an approximately 15% partial and/or complete remission. For humans, the present invention is quite unexpected and superior in its treatment of pancreatic cancer. As reflected in the Figure, the patient who was started on May 22, 1996 initially had a CA 19-9 antigen count well above 40,000 and a carcino-embryonic antigen (CEA) level well above 100. After about 60 days of treatment with 9-nitro-20(S)-camptothecin, these levels dropped below 10,000 for the CA 19-9 antigen count and below 20 for the CEA count. Clearly, the unexpected and quite effective results of treating patients with camptothecin compounds can be seen with these results since these two antigen counts are directly related to the presence of pancreatic cancer in humans. It is clear from these studies, that CPT and its derivatives with the closed lactone ring have been demonstrated to possess an astonishing level of anticancer activity with respect to pancreatic cancer in humans. The method of the present invention has been able to block growth completely and to totally regress human pancreatic cancer. This has been accomplished without any observable toxicity. Other embodiments of the present invention will be apparent to those skilled in the art from consideration of the specification and practice of the present invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
FreePatentsOnline.com. All rights reserved.